Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. - Wikidata - wikimedia - TriplyDB

Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.

Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.

http://www.wikidata.org/entity/Q34743488

about

Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Onco A multifactorial 'Consensus Signature' by in silico analysis to predict response to neoadjuvant anthracycline-based chemotherapy in triple-negative breast cancer.Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17.Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Co The Pathological Response to Anthracycline is Associated with Topoisomerase IIα Gene Amplification in the HER2 Breast Cancer Subset Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers.Synthesis and evaluation of (18)F-labeled ATP competitive inhibitors of topoisomerase II as probes for imaging topoisomerase II expression.PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance.Allelic imbalance at the HER2/TOP2A locus in breast cancer Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.Adjuvant trastuzumab in HER2-positive breast cancer.Texture analysis on MR images helps predicting non-response to NAC in breast cancer HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.Adjuvant therapy for HER2+ breast cancer: practice, perception, and toxicity.Poor-prognosis estrogen receptor- positive disease: present and future clinical solutions Association of HER-2 copy number and HER-2/CEP-17 ratio with neoadjuvant taxane-containing chemotherapy sensitivity in locally advanced breast cancer MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy.Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study Adjuvant treatment of HER2-positive breast cancer: winning efforts continue to improve HER2-positive patient outcome long-term.Prognostic significance of TOP2A gene dosage in HER-2-negative breast cancer Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab.Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues Regarding Dual HER2-Targeted Therapy.Dual functions of the homeoprotein DLX4 in modulating responsiveness of tumor cells to topoisomerase II-targeting drugs.Mechanisms of doxorubicin resistance in hepatocellular carcinoma Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial.Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial.DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes.Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status Quantum dot-based immunofluorescent imaging and quantitative detection of TOP2A and prognostic value in triple-negative breast cancer.Breast Cancer Biomarkers: Utility in Clinical Practice.Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group.An siRNA screen identifies the GNAS locus as a driver in 20q amplified breast cancer.HER2/neu, Topoisomerase 2a, Estrogen and Progesterone Receptors: Discordance between Primary Breast Cancer and Metastatic Axillary Lymph Node in Expression and Amplification Characteristics.P53 and its molecular basis to chemoresistance in breast cancer.Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?

P2860

Q26743510-7D9A8BB7-B7F5-40FF-A585-5DB49D5BC586 Q28728830-519C744C-87FF-4AAC-A424-EEA6F9B74CBE Q33739381-1F2A1C7A-B22E-4FC3-8B34-50E606D3FC0B Q33914753-3B89D19F-AA10-4D60-8876-6D149B1A904D Q34010867-148C6644-0F04-4941-977E-F56C9D6BDD94 Q34023749-133B7B95-2102-4CA3-A046-26F6FD5523CE Q34485373-DE47DDA3-710B-4046-931A-F53E1F19B23B Q34640536-4F8E69D4-A161-420B-9B25-A953C97992FA Q35021644-9AF0B602-D031-4D52-ACAB-FE53BC26B59A Q35029573-3F0E2258-653D-46AC-AC74-FB0270F4F44C Q35525919-1DDFB095-DAAA-4B9F-BA17-321E4EE486AB Q35562967-11A2FE2B-B493-4B1D-88F2-71DCF0BAC2B7 Q35663036-EEED83CC-4AC8-43A3-BF63-FC2642F7AA2A Q35663809-5E57A097-7428-415D-80BA-043119DBA266 Q35710898-0904A2F0-9C66-495A-83AB-07D345CC201D Q35737991-4E4E504F-2EE4-4F37-8D67-56FE36A01B14 Q35744973-50F83592-BFEF-4B15-BA12-2B2AA8D58790 Q35896366-4D867D03-D753-49E5-B4E6-8AC1F87891A9 Q35949291-CF3DEEC4-63B8-4F53-B06C-E271FC8A11AC Q36051500-66D5F65E-2BFC-4F70-B1A4-1A294AD7821F Q36117367-B27B46E2-9084-4C1E-8347-D8424E16C499 Q36151341-931E45A3-3FCA-4993-B3E5-20C21D439189 Q36245470-C63F6D06-7A87-48BC-B9DC-4D66A80B49F9 Q36349584-D5DA61EA-717A-4216-A72A-1A63EB9D9646 Q36402262-69E94773-430C-4E9E-875A-D4F239F03496 Q36440625-CB0A9872-EE31-4F00-997A-5E33DE8D2654 Q36545168-95BE4724-64FE-4BB2-B296-97A2089BBFE9 Q36687760-3265E89A-CD88-4923-ACC9-A470DABA89B0 Q36950483-064596F3-DD68-4029-99C6-44C9AE88D84B Q37095799-EB7B895A-666E-4B9E-82CD-10473A085EEC Q37247163-B83E1FCD-6919-4329-B0C4-114EE7B55357 Q37324977-A017D16B-ABEE-4B3A-87C3-F61F0C594D79 Q37376754-19096759-030E-48FD-8ECD-08B9F0570932 Q37441159-AC3716E7-EE11-4393-A132-BA03BA01E3FF Q37636623-0822F5D3-F1AB-42ED-AFCB-381DCC300BA2 Q37638287-03BDFE42-DF4D-4BDE-927C-B62824484DD8 Q37676107-558347C2-F65F-4022-A24B-E804FD4C9E30 Q37677735-30C4BB37-0711-48EA-9937-B4D56B4D2E8D Q37982133-ED22C451-CC6F-41AA-A6C2-168B39E6B190 Q37989074-B22F345C-86F3-44EB-8DBC-FEC6F4F7D6C2

P2860

Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.

http://www.wikidata.org/entity/Q34743488

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Alteration of topoisomerase II ...... hracycline-based chemotherapy.

@ast

Alteration of topoisomerase II ...... hracycline-based chemotherapy.

@en

Alteration of topoisomerase II ...... hracycline-based chemotherapy.

@nl

type

label

Alteration of topoisomerase II ...... hracycline-based chemotherapy.

@ast

Alteration of topoisomerase II ...... hracycline-based chemotherapy.

@en

Alteration of topoisomerase II ...... hracycline-based chemotherapy.

@nl

prefLabel

Alteration of topoisomerase II ...... hracycline-based chemotherapy.

@ast

Alteration of topoisomerase II ...... hracycline-based chemotherapy.

@en

Alteration of topoisomerase II ...... hracycline-based chemotherapy.

@nl

P1433

Q34743488-BF126A5F-7C14-4B2E-BDDB-7F3C215A1794

P1476

Q34743488-71483465-8F09-4248-82BE-7B46B38EC6C8

P2093

Q34743488-17DF4C3A-07F6-4FA1-B6E8-DE649BFB0AFA

Q34743488-2C18D498-F51C-4C3D-B8E9-8D97148E77CF

Q34743488-4FFCB72A-58A1-4B0C-9ABD-9FF480CA0DA0

Q34743488-6AC7B6D7-87CB-46CA-B593-5A1D6C7F8625

Q34743488-7806CC43-9DBB-4D8E-855A-A304E685795E

Q34743488-83F7CCDA-589F-4D58-8C43-97B461D0CEE9

Q34743488-8D1DF6FE-512A-4F71-A712-F4BB91A08B7F

Q34743488-97AD5939-CEE5-4E4F-AB60-950E1B1D17E4

Q34743488-9ACA38FE-2F98-4D05-9877-879341BCB786

Q34743488-AFA3E728-4348-4AFF-8588-A0CAC1BD3407

P2860

Q34743488-02E7E568-0C71-40A7-851B-84BD1F0715FE

Q34743488-05AFA751-46A6-4D9E-B0F6-C89EC4A978FF

Q34743488-06511AC5-98CE-4BF2-9D77-0934B89E2C90

Q34743488-09784DA4-DD6E-4AE3-AF64-A968ED9E4733

Q34743488-0BD6E75E-318D-41E7-A36D-A41554A5AC28

Q34743488-11288C09-5701-4542-BDE2-31CA853C4B1A

Q34743488-12CD8730-12E8-4666-B833-2DF92B4912E4

Q34743488-15FDA894-8CCF-402E-9CE2-BE0F5622246B

Q34743488-191CB4C2-5E74-462F-8E7B-9467B6E3E2F2

Q34743488-21967495-2907-474B-A3FA-7952666726D8

P304

Q34743488-0D03BEB9-2174-49A7-9D10-D48938E4F059

P31

Q34743488-BEB03950-7555-4816-9036-072AE57DD760

P356

Q34743488-B38FA7E1-BBC0-462B-B582-508237E49C0A

P407

Q34743488-4E172D02-5304-4301-A3B0-B619B24072CB

P433

Q34743488-BF1C2DF7-FDB1-48BD-A8C5-BBFD65C876C5

P478

Q34743488-B7C5A40C-2B41-49ED-936C-A2C3EC51733F

P50

Q34743488-348D478F-A5FB-4136-91AD-278D0DC4A913

Q34743488-46A155D3-18EE-41B7-AFF5-1B360C7AC6A2

Q34743488-B7626D0F-99B3-4768-8AD8-5953EE43F499

Q34743488-C43554EC-14B7-4A5A-9B13-E89A3DFEE082

Q34743488-D0127985-E695-41AB-9AC9-72CBF981258B

Q34743488-F97D0116-DF2E-4058-B638-032EE7C36781

P577

Q34743488-8B465C1F-41C9-4549-8C1E-98896F442BE5

P698

Q34743488-33B84664-9E36-462B-B199-DDD394382C21

P921

Q34743488-33FD8396-54E9-4601-AD59-5A3ED98D3697

P932

Q34743488-81055149-82B1-4426-A2D3-C45019B5EE9E

P356

JCO.2009.27.5644

P1433

Journal of Clinical Oncology

P1476

Alteration of topoisomerase II ...... hracycline-based chemotherapy.

@en

P2093

Alessandro Riva

http://www.w3.org/2001/XMLSchema#string

Angela Santiago

http://www.w3.org/2001/XMLSchema#string

Dennis J Slamon

http://www.w3.org/2001/XMLSchema#string

Giovanni Pauletti

http://www.w3.org/2001/XMLSchema#string

Guido Sauter

http://www.w3.org/2001/XMLSchema#string

Henry Taupin

http://www.w3.org/2001/XMLSchema#string

Ivonne E Villalobos

http://www.w3.org/2001/XMLSchema#string

John Crown

http://www.w3.org/2001/XMLSchema#string

Kerry J Flom

http://www.w3.org/2001/XMLSchema#string

Mary-Ann Lindsay

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of four novel human genes amplified and overexpressed in breast carcinoma and localized to the q11-q21.3 region of chromosome 17

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Topoisomerase IIalpha gene (TOP2A) amplification and deletion in cancer--more common than anticipated

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.

Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials.

HER-2 and topoisomerase II as predictors of response to chemotherapy.

HER-2/neu and topoisomerase IIalpha in breast cancer.

Adjuvant trastuzumab in HER2-positive breast cancer.

P304

859-867

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.27.5644

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

Tadeusz Pieńkowski

Wolfgang Eiermann

Isabelle Tabah-Fisch

Leslie Bernstein

P577

2010-12-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21189395

http://www.w3.org/2001/XMLSchema#string

P921

P932

3068060

http://www.w3.org/2001/XMLSchema#string